Literature DB >> 8957266

Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains.

D M Helmeste1, S W Tang, W E Bunney, S G Potkin, E G Jones.   

Abstract

[3H]Nemonapride differentially defines sigma and dopamine receptor sites depending upon assay conditions. In post-mortem schizophrenic brain tissues, [3H]nemonapride-labeled sigma receptor binding is decreased compared to match normal controls. No striatal dopamine D4/D4-like receptor differential was observed between the schizophrenic or control tissues, using the [3H]nemonapride minus [3H]raclopride subtraction method.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8957266     DOI： 10.1016/s0014-2999(96)00702-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  3 in total

1.  Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects.

Authors:  Jiali Chen; Guangying Li; Pingping Qin; Jiaojiao Chen; Na Ye; John L Waddington; Xuechu Zhen
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

Review 2.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies.

Authors:  Naohiko Uchida; Hiroshi Ujike; Kenji Nakata; Manabu Takaki; Akira Nomura; Takeshi Katsu; Yuji Tanaka; Takaki Imamura; Ayumu Sakai; Shigetoshi Kuroda
Journal:  BMC Psychiatry       Date:  2003-10-21       Impact factor: 3.630
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.